

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 600 CONGRESS AVENUE, SUITE 2400 AUSTIN, TEXAS 78701 RECEIVED

JUN 2 8 2001

TECH CENTER 1600/2900

FILE: 10025109/HACK:009

AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

WRITER'S INTERNET ADDRESS: TBOYCE@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER: 512/536-3043

June 13, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

37 C.F.R 1.8

Date

Thomas M. Boyce

Commissioner for Patents Washington, DC 20231

RE:

SN 09/065,082 "HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL VASCULARIZATION" - P.E. Rakoczy and I.J. Constable (Client Ref.

VS:SJB:BK:FP5962)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) An Amendment; and Response to Office Action dated December 13, 2000;
- (2) A Request for an Extension of Time of three months to and including June 13, 2000;
- (3) Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g) and Disk;
- (4) Substitute Paper Sequence Listing and computer readable form;
- (5) A check for \$890.00 as the fee for the extension of time; and
- (6) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or

Commissioner for Patents June 13, 2001 Page 2

should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10025109.

Respectfully submitted,

Thomas M. Boyce

Reg. No. 43,508

TB:SF Encl.